Vertex Pharmaceuticals (VRTX) closed at $489.43 in the latest trading session, marking a +0.84% move from the prior day. This move outpaced the S&P 500's daily gain of 0.13%. At the same time ...

As you can see from the chart above the percentage of shares that are sold short for Vertex Pharmaceuticals has declined since its last report. This does not mean that the stock is going to rise ...

Most investors are happy if a stock doubles within four or five years. Vertex Pharmaceuticals (NASDAQ: VRTX) shareholders should be ecstatic. Its share price has skyrocketed 140% over the last ...

My name is Olivia Brayer. I'm a senior Biotech Analyst here at Cantor. And we're really excited to have the Vertex IR team with us. We have Susie Lisa who is Senior Vice President, and Manisha Pai ...

Shares of Vertex Pharmaceuticals Inc. VRTX shed 0.07% to $470.78 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.45% to ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 20 years by 13.03% on an annualized basis producing an average annual return of 21.14%. Currently, Vertex Pharmaceuticals has ...

Shares of Vertex Pharmaceuticals Inc. VRTX inched 0.28% higher to $481.24 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the other biotech stocks. As we have mentioned in our article, “10 Best ...

Vertex stock is significantly undervalued due to the underestimated potential of its pain treatment drug, VX-548, which could become a blockbuster. VX-548 has shown to be more effective than ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...